菜单

Expert Viral Clearance Validation for Animal-Derived Medical Devices

A Biologics Bridge to Medical Devices

WuXi Biologics extends its proven virus clearance expertise from biologics to animal-derived medical devices, including cardiac valves, bone grafts, blood filters, and tissue-engineered implants. These devices carry unique viral risks from animal- or human‑donated source materials. To achieve global approvals, the risks must be rigorously controlled.

Contact Us Today

Navigating the Global Regulatory Landscape

Regulators worldwide—including FDA, EMA, NMPA, EU Notified Bodies, key APAC agencies—require robust viral inactivation or removal data for animal derived devices. Compliance with ISO 22442 and the FDA’s 2019 guidance (Medical Devices Containing Materials Derived from Animal Sources) is non-negotiable. From consultation to final report, our experts collaborate with clients to build a defensible, success-oriented validation strategy that ensures significant safety margins for your product.

Extensive Experience with Medical Device Products

Experience across a wide range of animal origins ensures that the correct model viruses are selected for your specific risk profile.

Sources
porcine, bovine, ovine, avian, fish, insect, and human‑donated tissues
Tissues bone, tendon, dermal matrix, pericardium valve, small intestine submucosa, combs, fish skin, silk

Specialized Matrix Handling

Unlike liquid biologics, solid and semi‑solid devices pose challenges in virus spiking, extraction, and recovery. WuXi Biologics excels at processing material forms that standard labs often struggle with:

Solid tissues bone blocks, granules, cartilage, pericardium patches
Semi-solids and gels collagen sponges, hemostatic gels, hyaluronic acid
Complex structures heart valves, dermal matrices, decellularized scaffolds

Material‑specific approaches achieve robust recoveries and high, defensible log reduction values (LRVs) without compromising device integrity. Our approaches include vacuum‑assisted loading, high‑titer spiking, toxicity and interference pre‑studies, and large‑volume endpoint assays.

Tailored Virus Risk Assessment and Model Virus Strategy

We offer customized virus risk assessments that:

  • Identify relevant viral risks tailored to your sample’s origin, type, and traits
  • Select high‑purity, high‑titer model viruses (typically ≥ 7 log10 PFU/mL or TCID50/mL)
  • Selects the ideal model viruses for each critical process step to strengthen regulatory evidence

Validated Manufacturing Processes

Our custom selection process ensures relevance to your source material and manufacturing steps, maximizing the likelihood of regulatory acceptance. We design and execute viral clearance and inactivation studies across key processes:

Physical Gamma and E beam irradiation, heat treatment, calcination, drying and moist heat
Chemical Solvent or detergent, acid or base treatment, aldehyde cross linking, ethylene oxide, hydrogen peroxide, peracetic acid, ethanol
Chromatography and filtration Ion exchange, affinity and hydrophobic interaction chromatography, syringe- or device relevant filtration

Accelerate Your Path to Market

Navigating standards like ISO 22442 and other FDA guidance requires precision. WuXi Biologics takes a consultative approach that includes a custom pre-study risk assessment that pinpoints the ideal model viruses and crafts a bespoke strategy.

Global compliance One report accepted by FDA, EMA, NMPA, and PMDA
Rapid turnaround Typical projects are completed in 2 to 3 months
Proven track record Over 460 successful audits and advanced GLP-compliant labs back the service

Frequently Asked Questions

A: Extensive capacity and optimized workflows allow us to complete a typical quality-assured study with a final report in as little as 2 to 3 months. Timelines vary by device complexity, process steps, and virus panel. Contact us for an estimate.
A: There is no fixed number, but FDA and ISO standards generally target a significant safety margin (often ≥ 6 to 8 log10 cumulative LRV). We help you define defensible goals based on your specific risk profile.